Study of Lutathera for GEP-NET Before and After Surgery
This study is looking at using Lutathera (177Lu Dotatate), a targeted therapy, both before and after surgery for people with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Researchers want to see if this approach is safe and practical, and if it can help patients live longer without their cancer returning. You may be able to join if you have GEP-NETs that are Grade 1 or 2, have spread to lymph nodes or the liver, and your doctors believe surgery can remove most of the tumor. The main goal is to measure how many people have surgery without complications within six months.
- Study design
- This is an interventional study with a planned enrollment of 10 participants. The specific phase of the study is not provided.
- What's involved
- Participants will receive four administrations of Lutathera. Procedures like Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and PET/CT will be used for medical imaging.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint measures complication-free surgery at 6 months. Other objectives include assessing recurrence-free survival and overall survival, but specific follow-up durations are not provided.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Study of PRRT in Metastatic, WHO Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Brendan C Visser, MD · PRINCIPAL_INVESTIGATOR · Stanford Universiy
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Measure Complication free Surgery6 months
The feasibility of perioperative 177Lu Dotatate as part of the therapeutic regimen to treat metastatic neuroendocrine tumors (NETs) will be assessed on the basis of number and proportion of participants who undergo 2 cycles of complication free 177Lu Dotatate therapy followed by cytoreductive surgery without complications, expressed as a number without dispersion. Complications are defined as follows. * Radiation fibrosis * Hepatic fibrosis by histologic diagnosis * Hepatic insufficiency * Bowel anastamotic leak (if bowel surgery) * Distal pancreatic leak (if pancreas surgery)